Cost-Effectiveness Analysis and Cost-Benefit Analysis in Health Care: A Critical Narrative Review of Methodological Controversies and Contemporary Extensions
DOI:
https://doi.org/10.55489/njcm.170720266943Keywords:
Health economic evaluation, Cost-effectiveness analysis (CEA), Cost-benefit analysis (CBA), Health equity, Resource allocationAbstract
Cost-effectiveness analysis (CEA), most often implemented as cost-utility analysis (CUA) using the quality-adjusted life-year (QALY), and cost-benefit analysis (CBA) are frequently presented as alternative, competing frameworks for health resource allocation, distinguished primarily by whether health outcomes are expressed in natural/utility units or monetised. This review argues that this framing, while pedagogically convenient, obscures a more important and less settled set of questions that determine whether either framework produces decision-relevant results: how the cost-effectiveness threshold (or, equivalently, the shadow price of health) should be derived; whose costs, benefits, and preferences should count; how the distribution - not merely the sum - of costs and effects across the population should be valued; and how parameter uncertainty should influence both the decision and the research agenda that follows it. After briefly establishing the conceptual core shared by CEA and CBA through the net-benefit framework, this review provides a critical synthesis of four areas of active methodological development: the opportunity-cost-based threshold debate; distributional cost-effectiveness analysis (DCEA); extended cost-effectiveness analysis (ECEA) and its cross-sectoral CBA-like extensions; and value-of-information (VOI) analysis as a link between economic evaluation and research prioritisation. Multi-criteria decision analysis (MCDA) is discussed as a complementary, non-aggregative alternative where a single threshold-based metric is contested or unavailable. Each of these developments is illustrated with a detailed published case study - the UK Bowel Cancer Screening Programme (DCEA), HPV vaccination financing in China and rotavirus vaccination in Ethiopia and India (ECEA), and the empirical re-estimation of the NICE cost-effectiveness threshold (the threshold debate) - chosen because each demonstrates a setting in which the conclusions of an evaluation change materially depending on which of these methodological extensions is applied. The review closes with practical guidance for researchers on selecting and combining these frameworks, and identifies open questions that remain unresolved in the literature.
References
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford: Oxford University Press; 2015.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093-1103. DOI: https://doi.org/10.1001/jama.2016.12195 PMid:27623463
Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68-80. DOI: https://doi.org/10.1177/0272989X98018002S09 PMid:9566468
Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1-503. DOI: https://doi.org/10.3310/hta19140 PMid:25692211 PMCid:PMC4781395
Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P. Distributional cost-effectiveness analysis of health care programmes - a methodological case study of the UK Bowel Cancer Screening Programme. Health Econ. 2015;24(6):742-754. DOI: https://doi.org/10.1002/hec.3058 PMid:24798212
Cookson R, Griffin S, Norheim OF, Culyer AJ, editors. Distributional Cost-Effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs. Oxford: Oxford University Press; 2020. DOI: https://doi.org/10.1093/med/9780198838197.001.0001
Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine. 2013;31(42):4902-4910. DOI: https://doi.org/10.1016/j.vaccine.2013.07.014 PMid:23871824
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10-31. DOI: https://doi.org/10.1016/j.jval.2021.10.008
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5):722-732. DOI: https://doi.org/10.1177/0272989X12458348 PMid:22990087 PMCid:PMC5577377
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797. DOI: https://doi.org/10.1056/NEJMp1405158 PMid:25162885
Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, et al. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015;33(24):2830-2841. DOI: https://doi.org/10.1016/j.vaccine.2015.02.052 PMid:25770785
Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making - an introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1-13. DOI: https://doi.org/10.1016/j.jval.2015.12.003 PMid:26797229
Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kaló Z, et al. Multiple criteria decision analysis for health care decision making - emerging good practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(2):125-137. DOI: https://doi.org/10.1016/j.jval.2015.12.016 PMid:27021745
Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24(11):1055-1068. DOI: https://doi.org/10.2165/00019053-200624110-00003 PMid:17067191
Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of information analysis for research decisions - an introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value Health. 2020;23(2):139-150. DOI: https://doi.org/10.1016/j.jval.2020.01.001 PMid:32113617
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Prakash Patel

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.

